News and Announcements
ASX Announcement – Corporate Updates for Optiscan
- Published March 22, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Optiscan ASX Announcement Company Update Highlights:
- Optiscan expects additional cash receipts including from Carl Zeiss Meditec for in excess of $200k.
- Total cash receipts from end of February till end of April are expected to exceed $900k.
- Leading medical journal, Nature Biomedical Engineering, publishes study led by Memorial Sloan Kettering Cancer Centre researchers confirming the potential for Optiscan technology to be used for “…intraoperative, PARPi-FL-based in vivo imaging without tissue excision.”
To read the full announcement, click here.
About Optiscan
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
